Drug intelligence / Profile preview

human albumin

Development stage: Unknown
Lead developer: Tonghua Anrate Biopharmaceutical
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

Human albumin is a protein derived from human plasma or produced recombinantly. It is widely used in medical settings for various purposes, primarily as a plasma volume expander to restore circulating blood volume in conditions like hypovolemia, shock, and burns. It also plays a crucial role in maintaining oncotic pressure and transporting hormones, fatty acids, and other substances in the blood. Specific formulations, such as 20% or 5% solutions, are used depending on the clinical indication. It is also frequently utilized as a component in placebo solutions for clinical trials due to its inert nature and physiological compatibility.

Brand names: Albutein 20%Albutein 5%An Pu Lai Shi®
Other names: Recombinant Human Albumin Injection

Beyond the preview

Go deeper on human albumin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on human albumin.

Explore the full profile